BCT.V - BriaCell Therapeutics Corp.

TSXV - TSXV Delayed Price. Currency in CAD
Currency in CAD

Valuation Measures

Market Cap (intraday) 513.55M
Enterprise Value 312.24M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)16.25
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.91

Trading Information

Stock Price History

Beta (3Y Monthly) 1.23
52-Week Change 3-50.00%
S&P500 52-Week Change 33.49%
52 Week High 30.1750
52 Week Low 30.0450
50-Day Moving Average 30.0603
200-Day Moving Average 30.0839

Share Statistics

Avg Vol (3 month) 3129.47k
Avg Vol (10 day) 3213.78k
Shares Outstanding 5196.38M
Float 131.03M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short (Aug 30, 2019) 4196.53k
Short Ratio (Aug 30, 2019) 41.66
Short % of Float (Aug 30, 2019) 4N/A
Short % of Shares Outstanding (Aug 30, 2019) 40.10%
Shares Short (prior month Jul 31, 2019) 490.86k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 23/1
Last Split Date 3Dec 3, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Jul 31, 2018
Most Recent Quarter (mrq)Apr 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-126.13%
Return on Equity (ttm)-321.39%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -6.4M
Net Income Avi to Common (ttm)-6.24M
Diluted EPS (ttm)-0.0380
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)938.93k
Total Cash Per Share (mrq)0
Total Debt (mrq)419.12k
Total Debt/Equity (mrq)48.40
Current Ratio (mrq)1.46
Book Value Per Share (mrq)0.00

Cash Flow Statement

Operating Cash Flow (ttm)-5.66M
Levered Free Cash Flow (ttm)-3.98M